Company Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson Consumer Inc. to Acquire NeoStrata Company, Inc., a Leader in Dermocosmetics

[PR Newswire] – SKILLMAN, N.J., April 26, 2016 /PRNewswire/ — Johnson & Johnson Consumer Inc. (JNJ) announced today that it has entered into a definitive agreement to acquire NeoStrata Company, Inc., a global leader in dermocosmetics. The acquisition will include NeoStrata’s affiliates and parent company TriStrata, Incorporated, a privately-held company. Financial terms were not disclosed. “Drs. Ruey Yu and Eugene Van Scott formed NeoStrata in 1988 and continue to make significant contributions to the science of skincare. NeoStrata’s legacy in dermocosmetics will complement our global Consumer portfolio and enable us to deliver advanced skin care brands to consumers around the world,” said Jorge Mesquita, Worldwide Chairman, Consumer, Johnson & Johnson. Read more on this. Johnson & Johnson (JNJ) , currently valued at $311.44B, opened this morning at $113.45. Looking at today’s market, JNJ one day range is $112.65 to $113.56 and has traded between $81.79 and $114.19 over the past year. Priced at 17.22x this year’s forecasted earnings, JNJ shares are relatively expensive compared to the industry’s -6.63x forward p/e ratio. And for those looking to make a return holding the stock, the company pays shareholders $3.00 per share annually in dividends, yielding 2.65%. Consensus earnings for the current quarter by the 18 sell-side analysts covering the stock is an estimate of $1.68 per share, which would be $0.03 worse than the year-ago quarter and a $0.02 sequential increase. The full-year EPS estimate is $6.59 which would be a $0.39 improvement than last year’s full-year earnings. The quarterly earnings estimate is predicated on a consensus revenue forecast of $18.01 Billion. If reported, that would be a 1.24% increase over the year-ago quarter. More recently, Goldman upgraded JNJ from Sell to Neutral (Mar 14, 2016). Previously, Barclays downgraded JNJ from Overweight to Equal Weight. When considering if the stock is under or overvalued, the average price target is $115.78, which is 2.05% above where the stock opened this morning. See more in (NYSE:JNJ) Similar Articles: Stock Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson to Webcast Annual Meeting of Shareholders Company Update: Johnson & Johnson (NYSE:JNJ) – Jim Cramer’s Top Takeaways: Oracle, Johnson & Johnson Company Update (NYSE:JNJ): Johnson & Johnson Announces Agreement To Acquire Novira Therapeutics, Inc.